Pfizer Pipeline. May 10, 2012

Size: px
Start display at page:

Download "Pfizer Pipeline. May 10, 2012"

Transcription

1 Pfizer Pipeline May 10, 2012

2 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of May 10, Visit Pfizer.com/pipeline, Pfizer s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2

3 Table of Contents Pfizer Pipeline Snapshot 4 Cardiovascular & Metabolic Diseases 5 Inflammation & Immunology 6 Neuroscience & Pain 7 Oncology 9 Vaccines 10 Other Areas of Focus 11 Projects Discontinued Since Last Update 12 3

4 Pfizer Pipeline Snapshot Discovery Projects 3 programs advanced or are new Pfizer Pipeline Snapshot as of May 10, In Reg Total 87 Pipeline represents progress of R&D programs as of 5/10/12 Included are 64 NMEs, 22 additional indications, plus 1 biosimilar 6 Projects discontinued since last update Recent Approvals - ELELYSO (taliglucerase alpha) for treatment of adults with a confirmed diagnosis of type 1 Gaucher disease (U.S.) Discovery Projects 12 programs advanced or are new Pfizer Pipeline Snapshot as of February 28, In Reg Total 90 Pipeline represents progress of R&D programs as of 2/28/12 Included are 70 NMEs plus 20 additional indications 8 Projects discontinued since last update Recent Approvals - Vyndaqel (tafamidis meglumine) for treatment of treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy (EU) - Prevnar 13 Adult for prevention of pneumococcal pneumonia and invasive disease in adults 50 years of age and older (U.S.) - Inlyta (axitinib) for advanced renal cell carcinoma (U.S.) 4

5 Pfizer Pipeline May 10, 2012 Therapeutic Area Cardiovascular and Metabolic Diseases Compound Name Viviant Eliquis (apixaban) Mechanism of Action ( 3 through regulatory approval) Selective Estrogen Receptor Modulator Factor Xa Inhibitor Osteoporosis Treatment and Prevention (U.S.) Stroke Prevention in Atrial Fibrillation (U.S./EU) apixaban Factor Xa Inhibitor Venous Thromboembolism Prevention (U.S.) 3 Eliquis (apixaban) Factor Xa Inhibitor Venous Thromboembolism Treatment 3 PF Diabetes Mellitus-Type 2 2 PF Diabetes Mellitus-Type 2 2 RN316 (PF ) Hypercholesterolemia, Post Acute Coronary Syndrome in Diabetics (Biologic) 2 PF Diabetes Mellitus-Type 2 2 PF Diabetic Nephropathy 2 CVX 096 (PF ) Diabetes Mellitus-Type 2 (Biologic) 1 OAP-189 (PF ) Diabetes Mellitus-Type 2, Obesity (Biologic) 1 PF Diabetic Nephropathy 1 PF Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 1 PF Diabetes Mellitus-Type 2 1 New or 5

6 Pfizer Pipeline May 10, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) tofacitinib (CP ) JAK Inhibitor Rheumatoid Arthritis (U.S./EU) tofacitinib (CP ) JAK Inhibitor Psoriasis (Oral) 3 tofacitinib (CP ) JAK Inhibitor Ulcerative Colitis 3 PF Rheumatoid Arthritis 2 PF Ulcerative Colitis (Biologic) 2 Inflammation and Immunology anrukinzumab (IMA-638) Ulcerative Colitis (Biologic) 2 PF Crohn s Disease (Biologic) 2 PF tofacitinib (CP ) Crohn s Disease, Lupus, *Rheumatoid Arthritis (Biologic) Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn s Disease 2 2 PF (EXC 001) Dermal Scarring 2 PD Lupus (Biologic) 1 PF Rheumatoid Arthritis (Biosimilar) 1 New or Biosimilar Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 6

7 Pfizer Pipeline May 10, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) tafamidis meglumine Lyrica Transthyretin (TTR) Dissociation Inhibitor Alpha-2 Delta Ligand Transthyretin familial amyloid polyneuropathy (U.S.) Central Neuropathic Pain due to Spinal Cord Injury (U.S.) Celebrex COX-2 Chronic Pain (U.S.) Remoxy (King) Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain (U.S.) ALO-02 Oxycodonenaltrexone core (King) Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain 3 Neuroscience & Pain bapineuzumab Beta AmyloidInhibitor Alzheimer s Disease (Biologic) 3 Lyrica Alpha-2 Delta Ligand Peripheral Neuropathic Pain 3 Lyrica Alpha-2 Delta Ligand CR (once a day dosing) 3 tanezumab Nerve Growth Factor Inhibitor OA Signs and Symptoms (Biologic) (On Clinical Hold) 3 PF Schizophrenia 2 Eladur (King) Chronic Pain (Will return rights to develop and commercialize to DURECT effective August 30, 2012) 2 PF Stroke Recovery 2 tanezumab Cancer Pain (Biologic) 2 New or 7

8 Pfizer Pipeline May 10, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) PF Acute Pain, *Chronic Pain 2 PF (AAB-003) Alzheimer s Disease (Biologic) 1 Neuroscience & Pain (cont d) PF Schizophrenia, Sensorineural Hearing Loss 1 PF (SAM-760) Alzheimer s Disease 1 PF Migraine (Biologic) 1 PF Schizophrenia 1 PF Severe Chronic Pain 1 New or * Note: Additional indications in 1 8

9 Pfizer Pipeline May 10, 2012 (cont d) Therapeutic Area Oncology Compound Name crizotinib axitinib bosutinib dacomitinib (PF ) Xalkori (crizotinib) Inlyta (axitinib) Mechanism of Action ( 3 through regulatory approval) c-met-alk Inhibitor VEGF Tyrosine Kinase Inhibitor Abl and src-family kinase inhibitor pan-her Inhibitor c-met-alk Inhibitor VEGF Tyrosine Kinase Inhibitor Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer (EU) Advanced Renal Cell Carcinoma after failure of prior systemic treatment (EU) Previously Treated Chronic Myelogenous Leukemia (U.S.), Chronic Myelogenous Leukemia (EU) Previously Treated Advanced Non- Small Cell Lung Cancer ALK-Positive 1st and 2nd Line (supports full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer Advanced Renal Cell Carcinoma in treatment-naïve patients Inlyta (axitinib) VEGF Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant (Asia only) 3 Sutent Multiple Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant 3 Torisel inotuzumab ozogamicin FKBP-Rapamycin Associated Protein Renal Cell Carcinoma 2nd Line (after disease progression on or after Sutent therapy) Aggressive Non-Hodgkin s Lymphoma (Biologic) 3 3 inotuzumab ozogamicin Indolent Non-Hodgkin s Lymphoma, *Acute Lymphocytic Leukemia (Biologic) 2 axitinib Liver Cancer, Thyroid Cancer 2 New or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 9

10 Pfizer Pipeline May 10, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) dacomitinib (PF ) Cancer 2 PD Cancer 2 CVX 060 (PF ) Renal Cell Carcinoma, *Cancer (Biologic) 2 PF Endometrial Cancer, *Cancer 2 Oncology (cont d) Vaccines PF Endometrial Cancer, *Cancer 2 PF Cancer 1 PF Cancer (Biologic) 1 PD Cancer (in combination with PF ) 1 PF Cancer (Biologic) 1 PF Cancer (Biologic) 1 PF Cancer 1 ACC-001 (PF ) Alzheimer s Disease 2 MnB rlp2086 (PF ) 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF ) Adolescent Meningitis, *Infant Meningitis 2 Staph Aureus 2 New or * Note: Additional indications in 1 10

11 Pfizer Pipeline May 10, 2012 (cont d) Therapeutic Area Other Areas of Focus Compound Name Mechanism of Action ( 3 through regulatory approval) Taliglucerase alfa Enzyme Replacement Therapy Gaucher Disease (Biologic) (EU) Xiapex (EU) Clostridial Collagenase for Injection Peyronie s Disease (Biologic) (EU) 3 Eraxis/Vfend Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation Aspergillosis 3 Zithromax/chloroquine 5-OS Ribosome Inhibitor Malaria 3 bazedoxifeneconjugated estrogens Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms 3 bosutinib Autosomal Dominant Polycystic Kidney Disease 2 PF (filibuvir) Hepatitis C Virus 2 tofacitinib (CP ) Transplant Rejection, Dry Eye 2 PH Chronic Obstructive Pulmonary Disease 2 PF (GMI-1070) Vaso-occlusive crisis associated with Sickle Cell Disease 2 PNU Tuberculosis 2 RN6G (PF ) Age-Related Macular Degeneration (Biologic) 1 PF Chronic Obstructive Pulmonary Disease 1 PF Hemophilia (Biologic) 1 New or 11

12 Projects Discontinued from Development since February 28, 2012 Compound Name Mechanism of Action ( 3 through regulatory approval) PF Tourette s Syndrome 2 SBI-087 (PF ) Rheumatoid Arthritis, *Lupus (Biologic) 2 PF Osteoporosis Treatment and Prevention (Biologic) 1 PF Liver Fibrosis 1 PF Alzheimer s Disease 1 Vabicaserin (PF ) Schizophrenia 1 * Note: Additional indication in 1; development discontinued 12

Pfizer Pipeline. August 9, 2012

Pfizer Pipeline. August 9, 2012 Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information

More information

Pfizer Pipeline. February 28, 2012

Pfizer Pipeline. February 28, 2012 Pfizer Pipeline February 28, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)

More information

Pfizer Pipeline. November 8, 2012

Pfizer Pipeline. November 8, 2012 Pfizer Pipeline November 8, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information

More information

Pfizer Pipeline. As of May 12, 2011

Pfizer Pipeline. As of May 12, 2011 Pfizer Pipeline As of May 12, 2011 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)

More information

Delivering Scientific Advances That Impact Patients Lives

Delivering Scientific Advances That Impact Patients Lives Delivering Scientific Advances That Impact Patients Lives Geno Germano President / General Manager Specialty Care & Oncology Business Units J.P. Morgan Healthcare Conference January 11, 2011 Forward-Looking

More information

Pfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Morgan Stanley Global Healthcare Conference September 13, 2010

Pfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Morgan Stanley Global Healthcare Conference September 13, 2010 Pfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Morgan Stanley Global Healthcare Conference September 13, 2010 Forward-Looking Statements Our discussions during this

More information

Pfizer Pipeline. As of January 30, 2018

Pfizer Pipeline. As of January 30, 2018 Pfizer Pipeline As of January 30, 2018 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)

More information

Pfizer Pipeline. As of May 1, 2018

Pfizer Pipeline. As of May 1, 2018 Pfizer Pipeline As of May 1, 2018 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)

More information

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016 Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive

More information

Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals

Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed

More information

CHRONIC TREATMENT GUIDELINES

CHRONIC TREATMENT GUIDELINES CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic

More information

Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals

Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed

More information

Magellan Rx. A smarter approach to pharmacy benefits management

Magellan Rx. A smarter approach to pharmacy benefits management Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We

More information

R&D Pipeline (May 2010)

R&D Pipeline (May 2010) R&D Pipeline (May 2010) 1 Global development (1) Filed Stage in the Most Advanced Territory YM617 tamsulosin Alpha-1 receptor antagonist Lower urinary tract syndrome in male patients (June 2007) New indication

More information

Cardiovascular Health Controlling Both HDL And LDL is Important

Cardiovascular Health Controlling Both HDL And LDL is Important Cardiovascular Health Controlling Both HDL And LDL is Important Reducing the Risk of Coronary Heart Disease 3 Relative Risk In 4 Years 2 1 0 Increased Risk 25 55 85 HDL Cholesterol (mg/dl) 100 160 220

More information

Pharmacotherapy Handbook

Pharmacotherapy Handbook Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University

More information

Summary of Strategic Competitive Analysis and Publication Planning

Summary of Strategic Competitive Analysis and Publication Planning Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing

More information

How much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all

How much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all Family Health History Please answer each question as honestly as possible. There are no right or wrong answers to nay of the questions. It is important that you answer as many questions as you can. We

More information

(212) Investors Contact: Ryan Crowe (212)

(212) Investors Contact: Ryan Crowe (212) For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

More information

Major Health Awareness Days in 2016

Major Health Awareness Days in 2016 Major Health Awareness Days in 2016 Whole year International Year of Pulses January All summer Big Red BBQ (Kidney Foundation) National Cervical Health Awareness Month February Ovarian Cancer Awareness

More information

R&D Pipeline (November 2005)

R&D Pipeline (November 2005) R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)

More information

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1 Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma

More information

What prescribers need to know

What prescribers need to know HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical

More information

Phoenix Remembrance Life

Phoenix Remembrance Life Phoenix Remembrance Life Field Underwriting Guide For agent use only. Not for distribution to the public as sales literature. Phoenix Remembrance Life is whole life insurance underwritten on a simplified

More information

HELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA

HELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA SIMPONI ARIA (golimumab) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with MTX, active psoriatic arthritis, and active ankylosing

More information

R&D Pipeline (November 2006)

R&D Pipeline (November 2006) R&D Pipeline (November 2006) 1Japan (1)Filed Code No Generic Name (Filing Date ) Therapeutic Target Classification YM177 celecoxib (Dec 2002) Rheumatoid arthritis, osteoarthritis, low back pain, etc Cyclooxygenase-II

More information

Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)

Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be

More information

Premium Specialty: Pediatrics

Premium Specialty: Pediatrics Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium

More information

R&D Pipeline (May 2006)

R&D Pipeline (May 2006) R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence

More information

Actemra (tocilizumab) CG-DRUG-81

Actemra (tocilizumab) CG-DRUG-81 Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject

More information

Rayos Prior Authorization Program Summary

Rayos Prior Authorization Program Summary Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive

More information

Pfizer Announces Modification To Ongoing Tofacitinib FDA Post- Marketing Requirement Study In Patients With Rheumatoid Arthritis

Pfizer Announces Modification To Ongoing Tofacitinib FDA Post- Marketing Requirement Study In Patients With Rheumatoid Arthritis February 19, 2019 Media Contact: Neha Wadhwa M: +1 212-733-2835 E: Neha.Wadhwa@pfizer.com Investor Contact: Charles Triano O: +1 212-733-3901 E: Charles.E.Triano@pfizer.com Pfizer Announces Modification

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab

More information

Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine

Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine SMi Immuno-Oncology, London Loui Madakamutil, Ph. D Vice President, Head for Discovery Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine Sept 26-27 2018 Nektar Therapeutics San

More information

Pfizer Global Medical Grants Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals

Pfizer Global Medical Grants Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be Yes : Does the activity align with Pfizer s Primary Areas of Interest? (listed

More information

Simponi / Simponi ARIA (golimumab)

Simponi / Simponi ARIA (golimumab) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi

More information

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs January 201 DATE DAY TIME TOPICS January 04 January 11 January 1 January 25 9:00AM 9:00AM 9:00AM 9:00AM 1. Understanding Fibromyalagia 2. Diabetes

More information

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 January 201 DATE DAY TIME TOPICS TOTAL January 04 1. Understanding Fibromyalagia 2. Diabetes and Cardiovascular Disease 3. Prostate Cancer 4. Hepatitis C 5. Understanding Hepatitis B January 11 1. Dysphagia

More information

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019

SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019 January 2019 DATE DAY TIME TOPICS TOTAL January 03 1. Alcoholism 2. Nutrition for the Elderly 3. Uterine Fibroids 4. HIPAA 5.Arthritis 6. Childhood Obesity January 10 1. Understanding Epilepsy: Latest

More information

List of Qualifying Conditions

List of Qualifying Conditions List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)

More information

*Compounds with "In-house" in this column include ones discovered by collaborative research.

*Compounds with In-house in this column include ones discovered by collaborative research. AGS67E Lymphoid malignancies P-I Injection In-house (ADC technology in-licensed from Seattle Genetics) AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, EuCODE license from Ambrx)

More information

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of

More information

Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus

Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with

More information

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College

More information

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),

More information

CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER

CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.

More information

2016 Health and Wellness Observances

2016 Health and Wellness Observances 2016 Health and Wellness Observances January 2016 Notes HealthCom Cervical Health Awareness Month National Birth Defects Prevention Month Cervical Cancer Screening Month National Blood Donor Month National

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)

More information

Professional International Study Management

Professional International Study Management Professional International Study Management Services Phase I Study Consulting Phase II-IV IV Study Conduct for Drugs and Devices Protocol Design and Development Study Feasibilities Site Identification,

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda) RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic

More information

Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.

Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. BACKGROUND Your Host: Eric Bricker, MD Co-Founder & Chief Medical Officer - Compass Professional Health Services

More information

Intron A. Intron A (interferon alfa-2b) Description

Intron A. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.07 Subject: Intron A Page: 1 of 6 Last Review Date: June 22, 2018 Intron A Description Intron A (interferon

More information

R&D Pipeline (As of April 2017)

R&D Pipeline (As of April 2017) R&D Pipeline (As of April 2017) Underlined items indicate changes from the previous announcement on January 31, 2017. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Metastatic castration-resistant

More information

2015 PQRS Registry. Source Measure Title Measure Description CITIUS1

2015 PQRS Registry. Source Measure Title Measure Description CITIUS1 1 CQ-IQ covers 65 CMS defined measures that Eligible Providers (EPs) have to report on to assess quality of care provided to the patients. Version Supported: PQRS Registry 2015 65 measures Reporting Period:

More information

Jefferies Healthcare Conference. June 6, 2018

Jefferies Healthcare Conference. June 6, 2018 Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private

More information

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz

More information

January Intravenous Nurse Day ALL MONTH LONG SUN MON TUE WED THU FRI SAT. Blood Donor Month. Glaucoma Awareness Month

January Intravenous Nurse Day ALL MONTH LONG SUN MON TUE WED THU FRI SAT. Blood Donor Month. Glaucoma Awareness Month January 1 2 3 4 5 6 Blood Donor Month 7 8 9 10 11 12 13 Glaucoma Awareness Month Volunteer Blood Donor Month Cervical Health Awareness Month 14 15 16 17 18 19 20 Thyroid Awareness Month Birth Defects Prevention

More information

2018 MIPS Reporting Family Medicine

2018 MIPS Reporting Family Medicine 2018 MIPS Reporting Family Medicine Quality Reporting Requirements: Report on 6 quality measures or a specialty measure set Include at least ONE outcome or high-priority measure Report on patients of All-Payers

More information

Streptococcus pneumoniae CDC

Streptococcus pneumoniae CDC Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis

More information

Genentech Research & Early Development

Genentech Research & Early Development Genentech Research & Early Development Founders Research Centers 1 & 2 Founders Research Centers 1 & 2 Andrew Chan, M.D., Ph.D. Senior Vice President, Research Biology September 2017 gred focus areas Discovering

More information

Publication Plan 2017

Publication Plan 2017 Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 6 PURPOSE To establish basic understanding of indications and contraindications for transplantation of various organs. POLICY The N.C. Department of Correction, Division of Prisons, Health Services

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

proposed set to a required subset of 3 to 5 measures based on the availability of electronic

proposed set to a required subset of 3 to 5 measures based on the availability of electronic CMS-0033-P 143 proposed set to a required subset of 3 to 5 measures based on the availability of electronic measure specifications and comments received. We propose to require for 2011 and 2012 that EP's

More information

ESC 2018 Tafamidis Analyst Briefing. August 27, 2018

ESC 2018 Tafamidis Analyst Briefing. August 27, 2018 ESC 2018 Tafamidis Analyst Briefing August 27, 2018 1 Forward Looking Statements This presentation includes forward-looking statements about, among other things, a potential indication for Tafamidis for

More information

Reproducibility with zebrafish models of human health and disease

Reproducibility with zebrafish models of human health and disease Reproducibility with zebrafish models of human health and disease Monte Westerfield, University of Oregon, Eugene, USA Sponsored by the Office of the Director National Institutes of Health, the National

More information

Major R&D Pipeline As of January 2016

Major R&D Pipeline As of January 2016 Major R&D Pipeline As of January 2016 Therapeutic area Cardiovascular- Metabolics Phase 1 Phase 2 Phase 3 Application DS-1040 (Acute ischemic stroke / TAFIa DS-2330 (Hyperphosphatemia) DS-9231/TS23 (Thrombosis

More information

MEDICAL HISTORY FORM FOR FOLLOW-UP

MEDICAL HISTORY FORM FOR FOLLOW-UP MEDICAL HISTORY FORM FOR FOLLOW-UP ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: Whenever numerical responses are required, enter the number so that the last digit appears in the rightmost

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Rayos) Reference Number: CP.CPA.273 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL)

CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL) CHRONIC MEDICATION PROGRAMME INCLUDES PRESCRIBED MINIMUM BENEFIT CHRONIC DISEASE LIST (CDL) A. GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Conditions covered under KeyHealth s chronic medication benefit

More information

Infliximab/Infliximab-dyyb DRUG.00002

Infliximab/Infliximab-dyyb DRUG.00002 Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration

More information

Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists

Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists Measure Name Measure Domain Measure Focus Comment/Explanation CMS Value-based Purchasing Program (CMS VBP) AMI 30-day

More information

R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018.

R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018. R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Castration-resistant prostate

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

More information

Development pipeline (as of February 1, 2017)

Development pipeline (as of February 1, 2017) Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2016 (IFRS) 13 Development pipeline (as of February 1, 2017) Oncology Additional indication name

More information

WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER

WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Scheme Act Regulations that

More information

Evolve180 / Ideal Northwest Health Profile

Evolve180 / Ideal Northwest Health Profile Evolve180 / Ideal Northwest Health Profile ABOUT YOU First Name: Last Name: Address: City: State: Zip: Phone: Email: Date of Birth: Age: Height: Occupation: How did you find out about our program? Marital

More information

Intron A. Intron A (interferon alfa-2b) Description

Intron A. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.07 Subject: Intron A Page: 1 of 6 Last Review Date: June 24, 2016 Intron A Description Intron A (interferon

More information

Over. Signature of Patient/Parent/Guardian: Date: / / Date: / / Patient s Name: For ADULT Patients : Employer: Address: Occupation:

Over. Signature of Patient/Parent/Guardian: Date: / / Date: / / Patient s Name: For ADULT Patients : Employer: Address: Occupation: Date: / / Patient s Name: Address: Preferred Home: ( ) - Work: ( ) - Cell: ( ) - Text Message Reminders : Yes No Social Security #: Date of Birth: - - / / For ADULT Patients : Employer: Occupation: Spouse

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

Anesthesia Preoperative Patient History

Anesthesia Preoperative Patient History Anesthesia Preoperative Patient History Please Complete and BRING WITH YOU to Your Anesthesia Appointment Patient Name: Date of Birth: Phone Number: Kind of Surgery You are Having: Date of Your Surgery:

More information

Intron A. Intron A (interferon alfa-2b) Description

Intron A. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Page: 1 of 6 Last Review Date: June 19, 2015 Intron A Description Intron A (interferon

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi

More information

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

DATE OF BIRTH: MELANOMA INTAKE

DATE OF BIRTH: MELANOMA INTAKE MELANOMA INTAKE GENERAL INFORMATION How was your first diagnosed? (Check the diagnosis that describes your condition.) Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Basal Cell Carcinoma Other

More information

ITG Diet Health Status Intake Form

ITG Diet Health Status Intake Form Health Status Intake Form Date: Last Name: First Name: D.O.B: Address: City: ST: ZIP Phone: Cell: Email: Age: HT: WT: BMI: Fat %: Occupation: Sex: M F Marital Status: M S D W How did you hear about the

More information

Etanercept for Treatment of Hidradenitis

Etanercept for Treatment of Hidradenitis Home Search Browse Resources Help What's New About Purpose Etanercept for Treatment of Hidradenitis This study is currently recruiting patients. Sponsors and Collaborators: University of Pennsylvania Amgen

More information

CUMULATIVE ILLNESS RATING SCALE (CIRS)

CUMULATIVE ILLNESS RATING SCALE (CIRS) CUMULATIVE ILLNESS RATING SCALE (CIRS) The CIRS used in this protocol is designed to provide an assessment of recurrent or ongoing chronic comorbid conditions, classified by 14 organ systems. Using the

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

(U / Anti-HER3 antibody) n Pexidartinib (US) (PLX3397 / CSF-1R/KIT/FLT3-ITD. inhibitor)

(U / Anti-HER3 antibody) n Pexidartinib (US) (PLX3397 / CSF-1R/KIT/FLT3-ITD. inhibitor) Red: Major changes after the FY2015 Q3 financial announcement on January 29, 2016 Major R&D Pipeline Therapeutic area Oncology Cardiovascular- Metabolics Phase 1 Phase 2 Phase 3 Application n DS-3032 (US/JP)

More information

SECTION I: ACTIVE DIAGNOSES. Active Diagnoses in the Last 7 Days

SECTION I: ACTIVE DIAGNOSES. Active Diagnoses in the Last 7 Days SECTION I: ACTIVE DIAGNOSES Intent: The items in this section are intended to code diseases that have a relationship to the resident s current functional status, cognitive status, mood or behavior status,

More information

Egg Donor screening Questionnaire. How many years did you complete in high school?

Egg Donor screening Questionnaire. How many years did you complete in high school? Please tick ( ) and complete ALL questions. YOU YOUR PARTNER Full name Forename Surname Forename Surname Date of birth day / month / year day / month / year Address Height : Weight: Ethnicity Home Tel:

More information

EVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002)

EVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002) Acne Acrodermatitis Enteropathica Adrenal Support Age Related Cognitive Decline Alcoholism/Alcohol Withdrawal Alzheimer's Disease Amenorrhoea Anaemia Angina Anorexia Nervosa Anxiety Asthma Atherosclerosis

More information

In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed.

In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed. Name: SS# In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed. Patient Medical, Surgical and Family History Review

More information

CLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12

CLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12 Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Remicade (infliximab) DRUG.00002

Remicade (infliximab) DRUG.00002 Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous

More information